Routine share withholding; mechanical by default.
Loading…
Traded Jan 7, 2026 · Filed Jan 8, 2026
Incyte's Head of US Oncology sold $1.18M of Incyte shares. It happened by itself, for taxes or pay.
Written from the filing's own figures. OQRO describes what was reported and never tells you what to buy or sell
open market sale
Code S — open-market or private sale
~$1,184,064
Shares × reported transaction price
71 days after results of Oct 28, 2025, 34 days before results of Feb 10, 2026
Results dates are the company's own 8-K (Item 2.02). Many companies only let insiders trade in a window after results
Closed at $110.57 on Jan 7, 2026, at its 52-week high, after an 8% rise over the previous 30 trading days
52-week range $55.17 (Apr 10, 2025) to $110.57 (Jan 7, 2026), 100% of the way up, from 250 adjusted closes. 30 trading days earlier: $102.06 on Nov 21, 2025. Describes the past only, not a forecast
Footnote references vesting of compensation awards
Only flagged when a footnote says so; never inferred
FDA approved Zynyz on Dec 17, 2025, 21 days before this trade.
New use approved (efficacy supplement). Active ingredient: Retifanlimab-Dlwr. From openFDA. Dates only; no link between the two is implied
| After | Stock | S&P 500 | Difference |
|---|---|---|---|
| 7 days | -0.6% | -0.3% | -0.3% |
| 30 days | +2.0% | -0.0% | +2.0% |
| 90 days | -9.3% | -2.0% | -7.2% |
| 180 days | +9.7% | +7.4% | +2.3% |
Past results only. Not a forecast.
Routine share withholding; mechanical by default.
Routine share withholding; mechanical by default.
Compensation award — excluded from discretionary-purchase analysis.
